Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Feb;11(2):119-30.
doi: 10.1038/nri2916.

Phenotypical and functional specialization of FOXP3+ regulatory T cells

Affiliations
Review

Phenotypical and functional specialization of FOXP3+ regulatory T cells

Daniel J Campbell et al. Nat Rev Immunol. 2011 Feb.

Abstract

Forkhead box P3 (FOXP3)(+) regulatory T (T(Reg)) cells prevent autoimmune disease, maintain immune homeostasis and modulate immune responses during infection. To accomplish these tasks, T(Reg) cell activity is precisely controlled, and this requires T(Reg) cells to alter their migratory, functional and homeostatic properties in response to specific cues in the immune environment. We review progress in understanding the diversity of T(Reg) cells, T(Reg) cell function in different anatomical and inflammatory settings, and the influence of the immune environment on T(Reg) cell activity. We also consider how these factors affect immune-mediated disease in the contexts of infection, autoimmunity, cancer and transplantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Differing immunosuppressive mechanisms used by TReg cells in lymphoid vs. non-lymphoid tissues
(Left) TReg cells in secondary lymphoid tissues use multiple mechanisms to inhibit DC function and block initiation of autoimmunity or prevent tumor clearance. (Right) TReg cell production of IL-10 is essential for immunoregulation at mucosal tissues such as the intestines, lungs and skin. The relative importance of other immunosuppressive mechanisms used by TReg cells (shown in white box) in lymphoid vs. non-lymphoid tissues remains to be established
Figure 2
Figure 2. Functional Differentiation of Treg cells and Tconv cells
The differentiation of naive TH cells into functionally distinct effector subsets (TH17, TH1, TH2, induced TR) is dependent on the induction of key transcriptional regulators (RORγT, T-bet, GATA3, Foxp3) following TCR stimulation in conjunction with cytokine signaling/STAT activation. Comparably, thymic-derived Treg cells utilize specific molecular programs driven by STAT3, T-bet, or IRF4 to restrain particular types of immune responses orchestrated by distinct effector T cell subsets.
Figure 3
Figure 3. Modulation of TReg cell activity can be by different factors in the immune environment
(Left) The vitamin-A metabolite retinoic acid (RA) can boost TReg cell activity within the intestine by inducing Foxp3 expression in naïve T cells and directing the expression of gut-homing receptors on both TReg and iTReg cells. (Right) During TH17-driven inflammation, IL-6 impairs TReg cell activity both by directly blocking TReg function as well as by promoting TH17 differentiation at the expense of iTReg generation. (Middle) During type-1 inflammatory responses, such as Mtb infection, IFNγ and IL-12 direct TH1 differentiation. Coordinately, IFNγ produced in response to infection directs the differentiation of T-bet+ TReg cells that are specialized to restrain pro-inflammatory TH1 cells.

References

    1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775–787. - PubMed
    1. Horwitz DA. Regulatory T cells in systemic lupus erythematosus: past, present and future. Arthritis Res. Ther. 2008;10:227. - PMC - PubMed
    1. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004;199:971–979. - PMC - PubMed
    1. Ehrenstein MR, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 2004;200:277–285. - PMC - PubMed
    1. Lindley S, et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 2005;54:92–99. - PubMed